id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-343452-4m0ub9iv	Barkama, Ravit	Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019	2020-09-15		.txt	text/plain	4246	231	48	OBJECTIVES: To determine whether placental cell therapy PLacental eXpanded (PLX)-PAD (Pluristem Therapeutics, Haifa, Israel) may be beneficial to treating critically ill patients suffering from acute respiratory distress syndrome due to coronavirus disease 2019. DESIGN: Retrospective case report of critically ill coronavirus disease 2019 patients treated with PLacental eXpanded (PLX)-PAD from March 26, 2020, to April 4, 2020, with follow-up through May 2, 2020. Herein, we report the outcome of treating eight patients suffering from respiratory failure and ARDS due to COVID-19 with human placenta-derived mesenchymal-like stromal cells (PLX-PAD). In this case series, eight patients critically ill due to COVID-19 were treated with PLX-PAD, a placenta-derived mesenchymallike cell therapy. In this preliminary uncontrolled case series of eight critically ill patients with COVID-19 and ARDS, administration of PLX-PAD, a placenta-derived cell therapy, was followed by an overall improvement in the clinical status of most patients.	./cache/cord-343452-4m0ub9iv.txt	./txt/cord-343452-4m0ub9iv.txt